RxDoctor Payments Data

Mabel Ng

Medical · Tujunga, CANPI 1154679546

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 753 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,881in general payments, 2019–2025

Across 753 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AbbVie$3K
  • Novartis$2K
  • AstraZeneca$1K
  • GSK$1K
  • Johnson & Johnson$1K
  • plus $4K from 25 others

What the payments were for

  • Food & beverage$15,78199%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,881 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.

See all medical providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib26$162,712
Xeljanz XrTofacitinib Citrate22$135,280
ActemraTocilizumab12$26,023
Diclofenac Sodium78$15,315
Hydroxychloroquine Sulfate240$5,120
Diclofenac Epolamine12$4,450
Lidocaine30$3,965
Gabapentin236$2,557
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen101$2,440
MethotrexateMethotrexate Sodium91$1,980
Colchicine28$1,925
Febuxostat41$1,450
Mycophenolate Mofetil21$1,312
Nitro-BidNitroglycerin17$1,009
Celecoxib34$911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$2,567$162,71226 claims
Scilex Pharmaceuticals Inc.Colchicine$49$1,92528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.

Other medical in Tujunga

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →